Hakim Farhana, Salfi Roshan, Bhikshapathi Darna, Khan Abdullah
Department of Pharmaceutical Sciences, Career Point University, Kota, Rajasthan-325003, India.
Department of Pharmaceutical Sciences, TRR College of Pharmacy, Meerpet, Hyderabad- 500097, Telangana, India.
Anticancer Agents Med Chem. 2022;22(5):926-932. doi: 10.2174/1871520621666210524164351.
According to the global cancer report 2019, the burden of cancer will exceed more than 18 million, becoming one of the major causes of global mortality rate. There is a pressing need to establish novel drug candidates for cancer treatment, though many anticancer agents are available in the market owing to their adverse effects. In recent years, quinazoline and its derivatives have been considered as a novel class of cancer chemotherapeutic agents that show promising activity against different tumors.
To evaluate the anti-cancer potential of the novel class of quinazoline tethered acetamide derivatives against six different cancer cell lines.
A novel series of various substituted quinazolinone acetamides were synthesized through a feasible scheme. The synthetic scheme involves the conversion of benzoxazinone (from anthranilic acid and benzoyl chloride) intermediate to 3-amino quinazoline-4-one which further converted to the final amide by tethering with the propionyl chloride employing Schotten-Baumann Reaction conditions. All the synthesized derivatives characterized by IR, 1HNMR and MASS spectral methods and anti-cancer activity were evaluated by employing MTT assay for six cancer cell lines and one normal human cell line.
All the synthesized compounds were screened for anti-cancer activity against six cancer cell lines, including A 549 (lung), DU 145 (prostate), HT 29 (colon), MCF-7 (breast), SiHA (cervical), B16F10 (mouse skin melanoma) and one normal human fibroblast cell lines. All the compounds displayed a decent cytotoxicity profile when compared with the standard drug doxorubicin. Among the synthesized compounds (5a to 5n) tested, two compounds, 5f and 5g have demonstrated excellent cytotoxicity against SiHA and MCF-7 cancer cell lines.
Comparatively most of the compounds displayed decent cytotoxicity potential relative to the standard drug doxorubicin. Further investigations are needed to establish the detailed mechanism of action of the developed novel quinazolinone acetamides.
根据《2019年全球癌症报告》,癌症负担将超过1800万,成为全球死亡率的主要原因之一。尽管市场上有许多抗癌药物,但由于其副作用,迫切需要研发新的癌症治疗候选药物。近年来,喹唑啉及其衍生物被认为是一类新型的癌症化疗药物,对不同肿瘤显示出有前景的活性。
评估新型喹唑啉连接乙酰胺衍生物对六种不同癌细胞系的抗癌潜力。
通过可行的方案合成了一系列新型的各种取代喹唑啉酮乙酰胺。合成方案包括将苯并恶嗪酮(由邻氨基苯甲酸和苯甲酰氯制得)中间体转化为3-氨基喹唑啉-4-酮,然后在肖滕-鲍曼反应条件下与丙酰氯连接进一步转化为最终的酰胺。所有合成的衍生物通过红外光谱、1H核磁共振光谱和质谱方法进行表征,并通过MTT法对六种癌细胞系和一种正常人细胞系评估其抗癌活性。
对所有合成的化合物针对六种癌细胞系进行抗癌活性筛选,包括A549(肺癌)、DU145(前列腺癌)、HT29(结肠癌)、MCF-7(乳腺癌)、SiHA(宫颈癌)、B16F10(小鼠皮肤黑色素瘤)和一种正常人成纤维细胞系。与标准药物阿霉素相比,所有化合物均表现出良好的细胞毒性谱。在所测试的合成化合物(5a至5n)中,两种化合物5f和5g对SiHA和MCF-7癌细胞系表现出优异的细胞毒性。
相对标准药物阿霉素,大多数化合物表现出良好的细胞毒性潜力。需要进一步研究以确定所开发的新型喹唑啉酮乙酰胺的详细作用机制。